German Firm Launches Phase 2a Study for COVID-19 Vaccine Candidate

Germany based CureVac N.V. announced on September 29, 2020, that the first participant has been dosed in the CV-NCOV-002 Phase 2a clinical trial of its COVID-19 vaccine candidate, CVnCoV. The dose-confirmation study is being conducted in the countries of Peru and Panama and will enroll a total of 690 healthy participants.

The CVnCOV vaccine study participants will receive 2 vaccinations at intervals of 28-days. Different dose levels will be investigated, starting at 6 µg, with the aim to confirm safety and evaluate the reactogenicity of the vaccine in older adults.